blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1

This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1



Thursday, 10 February 2011

Sarah Venn barrister "lost all faith" in Seroxat campaign cordinators


http://bobfiddaman.blogspot.com/2009/06/fiddaman-scott-simmons-harvey-sarah.html


From: Sarah Venn

Date: 06/18/04 16:25:13
To: Glitterari@aol.com
Subject: Re: Now I'm really confused



Hi

I'm at work at the moment, but will dig out the references. I certainly hope you aren't being impersonated as I was.

There are a lot of SUGS about...! I'm banned from most too!

I am aware of Susan Wolfe, she telephoned the police the night before a MIND protest outside the MHRA saying someone had threatened to suicide bomb it and nearly jeopardised the demo. It is best to steer well clear, I think she isn't getting all the support she needs.

I have had a lot of problems getting off Paxil, but am getting there, to my delight! I wish I have never been prescribed it and hope to god no one else ever is either.

I think GSK's behaviour is disgraceful. I have also lost all faith in those who were supposed to be co-ordinating the campaign over here.

If I can to do anything to help, I'd be very keen. As I said before, the media still ring me regularly and it would be nice to get them in touch with people who will keep things moving.



Sarah

Disrespectful, Uncaring or just downright liars - is Fiddaman talking about the MHRA or the Seroxat campaigners?

Disrespectful, Uncaring or just downright liars?

http://fiddaman.blogspot.com/2009/04/mhra-disrespectful-uncaring-or-just.html



I need to get something off my chest. What seemed a possibility has now been shrouded by utter contempt and ignorance. Maybe I'm being 'vexatious', a word often used by the MHRA when a member of the public disputes what answers the MHRA give them. In the past they have labelled Matthew Holford 'vexatious' and more recently, Strattera campaigner, Janne Larson has also been labelled 'vexatious'. Two people with two differing concerns regarding drugs licensed by the MHRA.



The MHRA can label me vexatious if it makes them feel better about their incompetence, because incompetent is what they are. Let me explain to you why.



On the 2nd of September 2008 I travelled, at my own expense, to London to meet with the MHRA. The meeting came about as a result of this blog and in particular the 'pot shots' I was aiming toward MHRA Chairman, Kent Woods. Of course, I was never given the reason why I was granted such a meeting, I just believe that my constant drum banging landed me my opportunity.



Former MHRA Communications Officer, John Watkins, was instrumental is setting up the said meeting and for that I owe him a great debt. I have no gripe with John, he is one of the good guys. He actually listened to patients and empathised with their plight. John has retired from the MHRA now which has left a huge brick wall facing many members of the public. Yes, someone else deals with 'complaints' now but there is no 'one on one' conversations... at least not to my knowledge.



During my meeting with the MHRA I raised the issue of SSRi withdrawal and how difficult it was for patients to taper off their particular SSRi with no guidance. The patient information leaflets [PILs] do not give the patient any advice whatsoever other than to withdraw slowly. How slowly?



I met with Kent Woods, a man I had previously lambasted on this blog. I had no problems looking Kent in the eye and to be honest he appeared to be a good host, he was charming and listened to what I had to say.



When I left the meeting I felt a sense of achievement. I had somehow managed to persuade Mr. Woods to meet with Dr. David Healy to discuss the withdrawal issue further. Dr. Healy and I have corresponded since and even he was surprised that I had got Kent to agree to meet with him.



7 months have passed since Kent Woods said to me that he would be happy to have the MHRA talk with Dr. Healy. David Healy has not been contacted by the MHRA.



Now, I can only assume that Kent Woods has either forgotten what he said or is being disrespectful and uncaring or... he was basically lying to me.



This morning I wrote the MHRA with the following:



It was addressed to Kent Woods and Sarah Morgan whom were both present at the meeting back in September. It was also addressed to MHRA Information and I copied Dr. Healy in.

----




Dear Kent, Sarah,



I am a patient man. One has to be when one has experienced a tapering of an SSRi over a period of 21 months.



My patience, however, is being tested to the limit with the MHRA and the proposals that were made at the meeting I had with you both back in September, 7 months ago.



Quite why no meeting has yet been arranged with yourselves and Dr. David Healy suggests to me that you are either, a, disrespectful or b, forgetful.



It takes less than a minute to pick up a phone to arrange a meeting with Dr. Healy, there surely is no red-tape to cut through over this issue is there?



I have been fair over this matter but it appears the proposal to meet with Dr. Healy was nothing more than a token gesture, it certainly appears that way to me as I'm sure it would to you both if you were in my position.



If GlaxoSmithKline or any other pharmaceutical company are not happy with you meeting someone who genuinely wants to help people taper of their drugs then please be forthright with me and have the decency to let me know.



7 months is more than ample time to arrange a meeting. I am certain if I pointed you toward an online pharmacy selling fake drugs you would move the earth to get a result.



People tapering from SSRi type drugs need help and 7 months of silence only goes to show just how much the MHRA seem to be bothered about this matter.



I would like an answer by the end of the working day. This is not rocket science and does not need lawyers.



I am very disappointed.



Regards



Bob Fiddaman



Seroxat Sufferers

http://fiddaman.blogspot.com



----



The MHRA have not replied and that saddens me deeply. It also annoys me because as the months have passed I have felt more and more disrespected by the people that regulate the drugs you and I take.



7 months is ample time to pick up a phone and arrange a meeting with someone. This has not been done. Things take time but I expect a regulator of drugs to act more rapidly on an issue that is causing so many people hardship.



The MHRA know how powerful blogging can be, only yesterday a press release was made regarding a new MHRA strategy for greater public and patient involvement. I believe that many advocates who have wrote to the MHRA have been part of that decision by the MHRA. We are people who want answers, we are people who take the drugs that the MHRA license.



We are people.



Personally, I see this 7 month wall of silence as an act of disrespect toward myself and the countless number of people who are struggling with SSRi withdrawal. I see it as an uncaring MHRA who would rather score points for pharma by closing down small online pharmacies for selling fake erection pills. I see it as the MHRA lying to me to keep me from 'bad mouthing' them on this blog.



Mr. Woods, you picked the wrong man. I take your lack of any response personally. I do not beleive that it could take 7 months to even consider making that phone call to Dr. Healy. Do not fob me off with 'it takes time', it doesn't wash.



You have let me down Mr. Woods. You have let all those down who are struggling to taper off SSRi's.



I have to ask myself whether or not proposals were made to the BNF. The 6 monthly publication was recently published - nothing about SSRi withdrawal.



I have offered to help the MHRA get a better understanding of withdrawal. Your silence and lack of response is a kick in the teeth.



7 months of doing nothing is not safeguarding public health. Whatever you have done 'behind the scenes' is not good enough.



You want the respect of the public and patients?



EARN that respect and carry through with whatever you say. Don't make false promises and don't lie to people!



Rant over.



Fid

SEROXAT not actually banned in minors - Fiddaman finally admits

Seroxat banned for children ...... nah, who would believe that?

Mark Harvey of Hugh James says - "nobody believed me"


Welcome to the club mate !

SEROXAT the worst SSRI ? - The Evidence is clear that it is not !








Does Seroxat have a capacity to cause asverse effects consequent upon or following discontinuance (withdrawl) such as prevent or make more difficult the ability of users to discontinue, withdraw from or remain free from taking Seroxat to a greater extent than all other Selective Serotonin Re-uptake Inhibitors (SSRIs)


http://www.blogger.com/goog_1281698931



No matter how he tried to ORCHESTRATE it, the truth is, that this was a transparent scam from the outset

Wednesday, 9 February 2011

This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime



This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1

KD Lang - Crying

Seroxat litigant given desk job @ Landrover - former Hugh James client exposed by Sunday Mercury

Worker On Sick Leave Returns

A MAN who claimed he was frozen out by Land Rover after being off sick has returned to work.

Production line worker Bob Fiddaman has not done a single hour's work for two years because the Solihull 4x4 specialist claims it could not find him an alternative job after he was struck down by osteoarthritis.

He remained on the company's long-term absence register despite being declared fit for non-manual work.

Following a Sunday Mercury story two months ago - in which we dubbed Mr Fiddaman, 36, from Yardley, Birmingham, 'Land Rover's Forgotten Man' - the company invited him in to discuss his situation.

He is now back at work on full-pay in a desk job which is due to last until September.




Mr Fiddaman said he was still planning to take Land Rover to tribunal, claiming discrimination.


Meanwhile, another employee on Land Rover's long-term absence register is also waiting to hear if another job has been found for him.


Solihull man David Busst, 49, went off sick from his job as a skilled fitter in 1992 but felt fit enough to return to non-manual work in 1996. He said company bosses had told him they could not find him another role.


A Land Rover spokesman said: 'Employees go on to the long-term absence register once their sick pay has been exhausted. When they reach a point where they feel they can return to work, we do what we can to find them employment on the site.





DESK JOB... Bob Fiddaman  





COPYRIGHT 2001 Birmingham Post & Mail Ltd

COPYRIGHT 2009 Gale, Cengage Learning

Seroxat litigant claims he lost his job @ Landrover - but was this just another false claim?



During those six years, I made one suicide attempt, separated from my wife and three  children and lost my job. The effects have had a devastating effect on my life

Seroxat "has made me a danger" - claims Bob Fiddling, but Bob claims a lot of things !

Seroxat "has made me a danger"

I am now Seroxat-free, coming off the drug 'cold turkey' over four months ago. This was my fourth attempt to come off after being prescribed them by my GP over six years ago.







During those six years, I made one suicide attempt, separated from my wife and three children and lost my job. The effects have had a devastating effect on my life.









Seroxat has changed me as a person - I no longer wish to be in social situations because I fear for the safety of whoever says the wrong thing to me.


A lot of my anger is vented toward the company that manufacture the drug, Glaxo SmithKlein (GSK), for their lies and deceit on the general public

Tuesday, 8 February 2011

Efexor Hallucinations - side effects 1 in 100 to 1000

Uncommon (affects 1 to 10 users in 1,000)




Bruising; black tarry stools (faeces) or blood in stools, which can be a sign of internal bleeding



Grinding of the teeth; involuntary movement of the muscles



Hallucinations



General swelling of the skin especially the face, mouth, tongue, throat area or hands and feet and/or a raised itchy rash (hives) may be present



Sensitivity to sunlight; abnormal hair loss; rash



Impaired coordination and balance; feeling dizzy (particularly when standing up too quickly), fainting, fast heartbeat



Weight gain; diarrhoea



Altered taste sensation



Lack of feeling or emotion; agitation



Ringing in the ears (tinnitus)



Inability to pass urine;



Abnormal orgasm (females)
 
source - http://www.medicines.org.uk/EMC/medicine/8609/XPIL/Efexor+XL/

Efexor - Patient Information Update - Change due to harmonisation of PIL

Change due to harmonisation of PIL

http://www.medicines.org.uk/EMC/history/8609/XPIL/Efexor+XL



NEW PIL here - click to view document (pdf)

Wyeth Pharmaceuticals

Huntercombe Lane South, Taplow, Maidenhead, Berks, SL6 0PH
Telephone: +44 (0)1628 604 377
Fax: +44 (0)1628 666 368
Medical Information Direct Line: +44 (0)845 367 0098
Medical Information e-mail: EUMEDINFO@Pfizer.com
Medical Information Fax: +44 (0)845 367 0777





Antipsychotic Use in Dementia 1999-2007 - shows significant decline from 2003

Antipsychotic Use in Dementia 1999-2007


Helen C. Kales, MD; Kara Zivin, PhD; Hyungjin Myra Kim, ScD; Marcia Valenstein, MD; Claire Chiang, MD; Rosalindo Ignacio, MS; Dara Ganoczy, MPH; Francesca Cunningham, PharmD; Lon S. Schneider, MD; Frederic C. Blow, PhD





Arch Gen Psychiatry. 2011;68(2):190-197. doi:10.1001/archgenpsychiatry.2010.200



Context Use of atypical antipsychotics for neuropsychiatric symptoms of dementia increased markedly in the 1990s. Concerns about their use began to emerge in 2002, and in 2005, the US Food and Drug Administration warned that use of atypical antipsychotics in dementia was associated with increased mortality.



Objective To examine changes in atypical and conventional antipsychotic use in outpatients with dementia from 1999 through 2007.



Design Time-series analyses estimated the effect of the various warnings on atypical and conventional antipsychotic usage using national Veterans Affairs data across 3 periods: no warning (1999-2003), early warning (2003-2005), and black box warning (2005-2007).



Subjects Patients aged 65 years or older with dementia (n = 254 564).



Main Outcome Measures Outpatient antipsychotic use (percentage of patients, percentage of quarterly change, and difference between consecutive study periods).



Results In 1999, 17.7% (95% confidence interval [CI], 17.2-18.1) of patients with dementia were using atypical or conventional antipsychotics. Overall use began to decline during the no-warning period (rate per quarter, –0.12%; 95% CI, –0.16 to –0.07; P < .001). Following the black box warning, the decline continued (rate, –0.26%; 95% CI, –0.34 to –0.18; P < .001), with a significant difference between the early and black box warning periods (P = .006). Use of atypical antipsychotics as a group increased during the no-warning period (rate, 0.23; 95% CI, 0.17-0.30; P < .001), started to decline during the early-warning period (rate, –0.012; 95% CI, –0.14 to 0.11; P = .85), and more sharply declined during the black box warning period (rate, –0.27; 95% CI, –0.36 to –0.18; P < .001). Olanzapine and risperidone showed declining rates and quetiapine showed an increase during the early-warning period, but rates of use for all 3 antipsychotics declined during the black box warning period. In the black box warning period, there was a small but significant increase in anticonvulsant prescriptions (rate, 0.117; 95% CI, 0.08-0.16; P < .001).



Conclusions Use of atypical antipsychotics began to decline significantly in 2003, and the Food and Drug Administration advisory was temporally associated with a significant acceleration in the decline.





Author Affiliations: Department of Veterans Affairs, Ann Arbor Center of Excellence, Serious Mental Illness Treatment, Research, and Evaluation Center, Ann Arbor, Michigan (Drs Kales, Zivin, Kim, Valenstein, Chiang, and Blow and Mss Ignacio and Ganoczy); Department of Psychiatry (Drs Kales, Zivin, Valenstein, Chiang, and Blow and Ms Ignacio) and Center for Statistical Consultation and Research (Dr Kim), University of Michigan, Ann Arbor; Veterans Affairs Center for Medication Safety, Patient Safety Center of Inquiry, and Pharmacoepidemiologic/Outcomes Research, Hines, Illinois (Ms Cunningham); and the University of Southern California Keck School of Medicine, Los Angeles (Dr Schneider).


http://archpsyc.ama-assn.org/cgi/content/short/68/2/190

Antipsychotic Treatment and Brain Volumes - Longitudinal Study of First-Episode Schizophrenia

Long-term Antipsychotic Treatment and Brain Volumes


A Longitudinal Study of First-Episode Schizophrenia

http://archpsyc.ama-assn.org/cgi/content/short/68/2/128

Beng-Choon Ho, MRCPsych; Nancy C. Andreasen, MD, PhD; Steven Ziebell, BS; Ronald Pierson, MS; Vincent Magnotta, PhD





Arch Gen Psychiatry. 2011;68(2):128-137. doi:10.1001/archgenpsychiatry.2010.199



Context Progressive brain volume changes in schizophreniaare thought to be due principally to the disease. However, recentanimal studies indicate that antipsychotics, the mainstay oftreatment for schizophrenia patients, may also contribute tobrain tissue volume decrement. Because antipsychotics are prescribedfor long periods for schizophrenia patients and have increasinglywidespread use in other psychiatric disorders, it is imperativeto determine their long-term effects on the human brain.



Objective To evaluate relative contributions of 4 potentialpredictors (illness duration, antipsychotic treatment, illnessseverity, and substance abuse) of brain volume change.



Design Predictors of brain volume changes were assessedprospectively based on multiple informants.



Setting Data from the Iowa Longitudinal Study.



Patients Two hundred eleven patients with schizophreniawho underwent repeated neuroimaging beginning soon after illnessonset, yielding a total of 674 high-resolution magnetic resonancescans. On average, each patient had 3 scans (2 and as many as5) over 7.2 years (up to 14 years).



Main Outcome Measure Brain volumes.



Results During longitudinal follow-up, antipsychotic treatmentreflected national prescribing practices in 1991 through 2009.Longer follow-up correlated with smaller brain tissue volumesand larger cerebrospinal fluid volumes. Greater intensity ofantipsychotic treatment was associated with indicators of generalizedand specific brain tissue reduction after controlling for effectsof the other 3 predictors. More antipsychotic treatment wasassociated with smaller gray matter volumes. Progressive decrementin white matter volume was most evident among patients who receivedmore antipsychotic treatment. Illness severity had relativelymodest correlations with tissue volume reduction, and alcohol/illicitdrug misuse had no significant associations when effects ofthe other variables were adjusted.



Conclusions Viewed together with data from animal studies,our study suggests that antipsychotics have a subtle but measurableinfluence on brain tissue loss over time, suggesting the importanceof careful risk-benefit review of dosage and duration of treatmentas well as their off-label use.







Author Affiliations: Departments of Psychiatry (Drs Ho and Andreasen and Messrs Ziebell and Pierson) and Radiology (Dr Magnotta), University of Iowa Carver College of Medicine, Iowa City.



Schizophrenia Drugs May Lead to Brain Tissue Loss - Bloomberg

Anti-psychotic drugs from AstraZeneca Plc and Johnson & Johnson may lead to loss of brain tissue or exacerbate declines in brain volume caused by schizophrenia, a study in the Archives of General Psychiatry found.


http://archpsyc.ama-assn.org/


http://archpsyc.ama-assn.org/cgi/content/short/68/2/128

Researchers tracked 211 patients with newly diagnosed schizophrenia to determine if the progressive loss of brain tissue widely attributed to the disease may be affected by drugs to treat it, severity of the illness or substance abuse. More antipsychotic drug treatment, including duration and intensity, was linked to greater declines in brain volume. Severity of disease, alcohol and illegal drug use had no effect.



“What we found was that medication treatments are probably one of the contributing factors to brain volume declines we see in people with schizophrenia,” said lead researcher Beng-Choon Ho, a psychiatrist at the University of Iowa’s Carver College of Medicine in Iowa City. “It’s not a wise thing to jump to the conclusion that this is bad, although intuitively it seems like the first thing that people will conclude. In reality, we still don’t quite understand what it means.”



Patients shouldn’t stop taking their medicines, which include London-based AstraZeneca’s Seroquel, Risperdal from New Brunswick, New Jersey-based J&J, Indianapolis-based Eli Lilly & Co.’s Zyprexa and a host of older, generic medications, the researchers said. Instead, they and their doctors should find the lowest effective dose, Ho said in a telephone interview.



“Pharmaceutical companies must continue the vigorous search for agents that are genuinely neuroprotective,” the researchers said.



1 in 100



Schizophrenia is a mental disorder affecting about 1 in 100 people that makes it hard to distinguish reality, think logically and behave normally in social settings, according to the National Institutes of Health. Drug treatment helps control severe symptoms, such as hearing voices or violent outbursts. They also can produce side effects such as weight gain, diabetes, and movement disorders.



The researchers used repeated high-resolution magnetic resonance scans starting in 1990 to track changes in brain volume over time. Each patient had an average of three scans and was followed for more than seven years. The study didn’t include a comparison group of untreated patients, which would have been unethical, Ho said.



“It is possible that, although anti-psychotics relieve psychosis and its attendant suffering, these drugs may not arrest the pathophysiologic processes underlying schizophrenia and may even aggravate progressive brain tissue volume reductions,” the researchers concluded.



The study also raises concerns about the widespread and growing use of anti-psychotic drugs for people without schizophrenia, including the elderly and those with other mental disorders, the researchers said.



To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net



To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net



via bloomberg.com

Monday, 7 February 2011

SEROXAT litigant took day off from cold turkey for Casbah Club gig

Bob said


"The current UK Seroxat litigation, of which I am a claimant, will be the subject of future posts on this blog. I've remained quiet due to legal reasons but will be going public with revelations shortly. Both ITV and BBC have already approached me. "




to read a review of the Casbah Club  gig go here - http://www.bigcountry.co.uk/news/articleRead.php?id=18
 
to confirm Bob had day off from cold turkey go here -
http://groups.yahoo.com/group/uksurvivors/message/52355
 
to learn how FIDDAMAN tried to gag this information go here - http://chillingeffects.org/N/42559
 
 

PAXIL ADDICTION STORY - but Prof Healy's research shows PAXIL is the easiest to withdraw from

Sunday, 6 February 2011

FIDDAMAN could learn from Darcy Baston & grow up !

GAME OVER



http://paxilprogress.org/itstime.html



Darcy: 1, Paxil: 0

It's time. I have to go. There are giggling and ticklish things on my horizon that I have yet to touch. There are things I have to do before I can break ties, but the process has begun and should only take a couple weeks.



6 years ago, I had a problem. I was stuck on Paxil. I was just beginning to figure out that what I felt when I tried to reduce my dosage wasn't just a resurfacing of a current condition, but a new challenge called withdrawal.



I hated it.



I hated it then. Today, I'm completely and amorously grateful for it. That difficult challenge brought me through some incredibly rewarding growth, and the privilege of meeting all of you.




What you have all shown me since the inception of paxilprogress is that very few people believe how truly miraculous we all are, despite it being reality. We our own miracle waiting to be set free. We're heroes. In a world without validation nor an open ear, we walked forward hand in hand, trusting in our own abilities and achieved dream after dream. Like a set of dominoes where each weighed a million pounds, all we had to do was focus on toppling the first, and the rest began to spill effortlessly.



You also showed me that we each have our own first domino, and before we push on the collective one, we have to set our own in motion. You come first. Your first step is your step of change. You make it possible and give it to yourself. Once together, this happened Plunk. Plunk. Plunk-Plunk,Pl-Pl-Pl-P-P-P-P-P-P-R-R-RRRRRRRRRROAR.



The world took notice and change began; because of you, because of me, because of us. Thanks for teaching me how that works. Thanks for showing me how just by pushing one's own domino, a world is changed. All that is needed is consistent repetitive focused choice, and the rest just works itself out.



This happens when one takes the time to let go of needing to control the time it takes.



The act of letting go is magical like that. Most of us believe that things have to be pushed away, as if facing anxiety, depression or Paxil withdrawal is a battle. That couldn't be farther from the truth. All those things are nonsenses we've held closely to ourselves, and we have to let them go to be free of them. We've all noticed that takes quite a bit of effort. As convincing that is an argument for the "but it's a fight" idea, it's not that something is hard to let go of. It's that at the core of our beings, we are so devoid belief that we are the answer to ourselves, that we fight the walls we've put up. What you push through is not depression, but your construction of it. What you push through is not anxiety, but your mortar solidifying it. You've been brick building and have either not noticed, or are making yourself forget because that self imposed ignorance is what the world (friends, family, chance encounters, radio ad, media segment, doctor's counsel, whatever) has taught you to do.



I've been ignorantly fighting the idea of leaving paxilprogress. I had convinced myself it was difficult. My inner dialogue was full of: "But who will do what you've done? Does anyone have your experience with communities, forums, web servers, anxiety and Paxil? Will it take several people to replace you?" Etc. Andrea reminded me how egoic and silly all that was (and echoed by Laurie, Rita, Christie and more), and I was brought back from my little lull in wisdom. Change happens with letting go, and not while trying to control within a context of self identity. So whatever happens, however paxilprogress grows and changes, I have faith people will do what they can for each other with just as much passion, and let go. "Freedom is in you" MEANS letting go of rationalization and realizing that all is well, if you stop calling it unwell. And as backwards as that sounds when there are people getting hurt, it's just the necessary space to affect real changes that alleviate suffering.


read on - http://paxilprogress.org/itstime.html




FIDDAMAN took a "day off" from cold turkey withdrawal - what an insult to those who have genuinely suffered under SSRI's



"My blog is called Seroxat Sufferers because I took Seroxat and had a pretty torrid time with it. Your argument about me attending a concert during my cold turkey period was pretty lame - do you not think being stuck in a one-bedroom flat dealing with Zaps, sweats, anger etc warrants a day off?"



source - http://groups.yahoo.com/group/uksurvivors/message/52355